Toronto Innovation Acceleration Partners ("TIAP") adds novel KRAS oncology project to its LAB150 portfolio

  • Toronto Innovation Acceleration Partners („TIAP“) announced today the launch of a new project developed under the BRIDGE LAB150, a partnership between Evotec SE and TIAP. The project will be focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member, and aims to develop therapeutics targeting the protein-protein interactions of KRAS and its downstream interacting partners. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter

    Du magst vielleicht auch